OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX) in a report released on Tuesday. The firm issued a sell rating on the stock.

Separately, Needham & Company LLC reiterated a “buy” rating and set a $4.25 price target on shares of OncoCyte in a report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, OncoCyte has a consensus rating of “Hold” and an average target price of $4.06.

OncoCyte Stock Performance

NASDAQ:OCX opened at $3.13 on Tuesday. The stock’s 50 day moving average price is $3.08 and its 200 day moving average price is $2.94. OncoCyte has a 52 week low of $2.08 and a 52 week high of $4.34.

OncoCyte (NASDAQ:OCX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.36) EPS for the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%. The firm had revenue of $0.10 million during the quarter.

Insider Transactions at OncoCyte

In related news, CFO Andrea S. James acquired 33,670 shares of the stock in a transaction dated Wednesday, October 2nd. The shares were acquired at an average price of $2.97 per share, for a total transaction of $99,999.90. Following the completion of the purchase, the chief financial officer now owns 33,670 shares in the company, valued at approximately $99,999.90. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of OncoCyte stock in a transaction that occurred on Wednesday, October 2nd. The stock was purchased at an average cost of $2.95 per share, with a total value of $3,880,250.05. Following the completion of the transaction, the insider now directly owns 6,244,405 shares in the company, valued at $18,420,994.75. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrea S. James bought 33,670 shares of OncoCyte stock in a transaction that occurred on Wednesday, October 2nd. The stock was purchased at an average cost of $2.97 per share, with a total value of $99,999.90. Following the completion of the transaction, the chief financial officer now owns 33,670 shares of the company’s stock, valued at $99,999.90. The disclosure for this purchase can be found here. 1.94% of the stock is currently owned by corporate insiders.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.